Skip to content
DataLookout
Menu

SAMHY2NCT05427461

Circulating " Cancer Cells / Macrophage " HYbrid Cells in Patients With Sarcoma, Part 2

StatusActive, Not Recruiting
PhaseNot applicable
Primary completion (estimated)

At risk: Primary completion moved at least 9 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 11 versions: 9 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Jul 2026 to May 2027
    • Eligibility criteria expanded, about 12 words
    • Primary endpoints: details revised at 1 of 1 entry
    • Secondary endpoints: details revised at 1 of 1 entry
  2. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v10
  3. Minor Start date changed from estimate of Jan 2023 to Jan 13, 2023v7
  4. Minor Start date: Dec 2022 to Jan 2023v6
  5. Notable Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v5
Show 3 earlier versionsHide 3 earlier versions
  1. Minor Site contact updatedv4
  2. Notable Start date: Oct 2022 to Dec 2022v3
  3. Notable Start date: Jul 2022 to Oct 2022v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

The longitudinal evolution of rate of patients with "cancer cell / macrophage" hybrid cells in peripheral blood.
Timeframe: 24 months after the end of inclusions.

Secondary (1)

Quantification of circulating hybrid cells in peripheral blood by automatic measurement (Cell Counter Corning) and expressed in number of cells / millilitre of blood.

Arms and interventions

Patient with leiomyosarcomaOther

Other: Blood samples will be collected at different times.

Sites

1 site in 1 country

  • Institut Universitaire du Cancer Toulouse - OncopoleToulouse, France